Despite major advances in identifying pathophysiological mechanisms of acute kidney injury (AKI), no definitive therapeutic or preventive modalities have been developed with the exception of dialysis. One possible approach is the control of inflammation and AKI through activation of the neuroimmune axis. The cholinergic anti-inflammatory pathway is thought to contribute to the homeostatic response in inflammation-related disorders and forms the basis for recent approaches toward therapeutic intervention. The concept is based on the emerging understanding of the interface between the nervous and immune systems. In the cholinergic anti-inflammatory pathway, the efferent vagus nerve indirectly stimulates the CD4+ T-cells in the spleen. The CD4+ T-cells produce acetylcholine, which stimulates alpha 7 nicotinic receptors (a7nAChRs) on macrophages. Activation of the a7nAChRs on macrophages in turn activates NF-κß and elicits an anti-inflammatory response. Recently, we demonstrated the effect of a non-pharmacologic, noninvasive, ultrasound-based method to prevent renal ischemia-reperfusion injury and sepsis-induced AKI in mice. Our data suggest that ultrasound-induced tissue protection is mediated through the activation of the cholinergic anti-inflammatory pathway. In addition, nicotinic receptor agonists and ghrelin, a neuropeptide, were reported to prevent AKI possibly through a mechanism closely linked with the stimulation of the vagus nerve. Based on the studies focusing on inflammation and the observations regarding kidney injury, we believe that activating the cholinergic anti-inflammatory pathway will be a new modality for the prevention and treatment of AKI.

Keywords:
Neuroimmunomodulation, Immunity, Inflammation, Acute renal failure, Vagus nerve, Kidney, Autonomic nervous system
1.
Uchino S: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813-818.
2.
Procaccini C, Pucino V, De Rosa V, Marone G, Matarese G: Neuro-endocrine networks controlling immune system in health and disease. Front Immunol 2014;5:143.
3.
Bellavance MA, Rivest S: The HPA - immune axis and the immunomodulatory actions of glucocorticoids in the brain. Front Immunol 2014;5:136.
4.
Pintér E, Pozsgai G, Hajna Z, Helyes Z, Szolcsányi J: Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions. Br J Clin Pharmacol 2014;77:5-20.
5.
Andersson U, Tracey KJ: Reflex principles of immunological homeostasis. Annu Rev Immunol 2012;30:313-335.
6.
Tracey KJ: Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007;117:289-296.
7.
Koopman FA, Schuurman PR, Vervoordeldonk MJ, Tak PP: Vagus nerve stimulation: a new bioelectronics approach to treat rheumatoid arthritis? Best Pract Res Clin Rheumatol 2014;28:625-635.
8.
Matteoli G, Boeckxstaens GE: The vagal innervation of the gut and immune homeostasis. Gut 2013;62:1214-1222.
9.
Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-874.
10.
Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-462.
11.
Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ: Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-388.
12.
Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov VA, Gallowitsch-Puerta M, Ashok M, Czura CJ, Foxwell B, Tracey KJ, Ulloa L: Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006;203:1623-1628.
13.
Martelli D, McKinley MJ, McAllen RM: The cholinergic anti-inflammatory pathway: a critical review. Auton Neurosci 2014;182:65-69.
14.
Rosas-Ballina M, Olofsson PS, Ochani M, Valdés-Ferrer SI, Levine YA, Reardon C, Tusche MW, Pavlov VA, Andersson U, Chavan S, Mak TW, Tracey KJ: Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011;334:98-101.
15.
Yeboah MM, Xue X, Duan B, Ochani M, Tracey KJ, Susin M, Metz CN: Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats. Kidney Int 2008;74:62-69.
16.
Rajan D, Wu R, Shah KG, Jacob A, Coppa GF, Wang P: Human ghrelin protects animals from renal ischemia-reperfusion injury through the vagus nerve. Surgery 2012;151:37-47.
17.
Khowailed A, Younan SM, Ashour H, Kamel AE, Sharawy N: Effects of ghrelin on sepsis-induced acute kidney injury: one step forward. Clin Exp Nephrol 2015;19:419-426.
18.
Gigliotti JC, Huang L, Ye H, Bajwa A, Chattrabhuti K, Lee S, Klibanov AL, Kalantari K, Rosin DL, Okusa MD: Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol 2013;24:1451-1460.
19.
Gigliotti JC, Huang L, Bajwa A, Ye H, Mace EH, Hossack JA, Kalantari K, Inoue T, Rosin DL, Okusa MD: Ultrasound modulates the splenic neuroimmune axis in attenuating AKI. J Am Soc Nephrol 2015, Epub ahead of print.
20.
Ben-Menachem E, Revesz D, Simon BJ, Silberstein S: Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability. Eur J Neurol 2015;22:1260-1268.
21.
Stacey WC, Litt B: Technology insight: neuroengineering and epilepsy-designing devices for seizure control. Nat Clin Pract Neurol 2008;4:190-201.
22.
Howland RH: Vagus nerve stimulation. Curr Behav Neurosci Rep 2014;1:64-73.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.